A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure.

Trial Profile

A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2015

At a glance

  • Drugs Bucindolol (Primary)
  • Indications Heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms BEST
  • Most Recent Events

    • 09 Sep 2015 Results of retrospective analysis of data to investigate effect of bucindolol in patients with atrial flutter were published in the Journal of Cardiac Failure and will be presented at the 19th Annual Scientific Meeting of the Heart Failure Society of America, according to an ARCA Biopharma Inc media release.
    • 09 Sep 2015 Results of retrospective analysis of data to investigate effect of bucindolol in patients with atrial flutter published in the Media Release.
    • 03 Jan 2013 Results from a post-hoc analysis of 1040-patient DNA substudy in this trial have been published in the Circulation: Arrhythmia and Electrophysiology according to an ARCA Biopharma media release. Results were also summarised in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top